This can be transformative, especially for women who feel they have spent decades fighting their appetite. But these medicines are powerful. Nausea, constipation, diarrhoea, vomiting, reflux, dehydration and gallbladder problems can occur. Rarely, serious complications such as pancreatitis require urgent medical attention.

We have covered this wider risk-benefit picture in The Hidden Dangers of the Weight Loss Jab and in our Mounjaro review.

So the issue is not whether GLP-1s “work”. They do! The issue is whether they are being used wisely.

Why menopausal women may respond differently

The evidence specifically in menopausal women is still developing. That matters.

Most large GLP-1 weight-loss trials include women, but they were not designed primarily as menopause studies.There are, however, important signals.

A 2024 study in postmenopausal women with overweight or obesity treated with semaglutide found that women using hormone therapy appeared to have a better weight-loss response than those not using hormone therapy. This does not prove that HRT “boosts” semaglutide in every woman, but it supports the idea that hormonal context may affect metabolic response. There is also growing interest in whether menopausal status affects body composition, appetite response, lean mass preservation and long-term weight maintenance during GLP-1 treatment.

The honest interpretation is this:

GLP-1s can be highly effective in midlife women, but menopause-specific prescribing should be more thoughtful than simply escalating the dose until the scales move.

That is especially important because a woman may be prescribed GLP-1 medication by one provider, HRT by another, and receive lifestyle advice from somewhere else entirely. In our view, those conversations should be joined up. That’s precisely how we work with our in-house GP.

HRT, testosterone and GLP-1s: get the hormonal foundation right

As we’ve already sad, GLP-1 medicines can help with appetite, cravings, glucose control and weight loss, but they are not menopause treatment. They do not replace oestrogen, progesterone or testosterone where these are clinically indicated. This distinction matters because menopause is a hormonal transition that affects sleep, mood, visceral fat, insulin sensitivity, bone density, urogenital health, muscle and cardiovascular risk. If a woman presents with midlife weight gain, fatigue, brain fog, poor sleep and low mood, she may not simply need an appetite suppressant. She may need a proper menopause review.

For patients needing specialist HRT input, we work closely with Dr Karen Benson, our in-house GP and HRT specialist. Dr Benson also works from Letchworth Pharmacy’s private GP clinic, where patients can access personalised GP-led support. You can also read more about our Private Menopause Clinic in Letchworth.

In general, transdermal oestrogen  (patches, gel or spray) is often preferred over oral oestrogen, particularly in women with metabolic or vascular risk factors. Oral oestrogen passes first through the liver, which can influence clotting factors, triglycerides, inflammatory markers and binding proteins. Transdermal oestrogen largely avoids this first-pass hepatic metabolism. This is especially relevant in women with central weight gain, raised triglycerides, insulin resistance, fatty liver risk, hypertension, migraine, obesity or other cardiovascular risk factors. Oral HRT is not necessarily contra-indicated but the route of administration should be chosen deliberately.

It is also relevant for women using GLP-1 medicines, because semaglutide and tirzepatide delay gastric emptying. The full impact on oral HRT absorption is not yet clear, but the British Menopause Society has highlighted this as an area where data are lacking. In practical terms, women using oral HRT, oral progesterone or oral contraception should make sure their prescriber knows they are using a GLP-1.

Progesterone still matters. For women with a uterus, oestrogen should generally not be used without appropriate endometrial protection. If a woman is experiencing nausea, vomiting, erratic medicine timing, unscheduled bleeding or gastrointestinal side effects while taking a GLP-1, her HRT regimen should be reviewed rather than ignored.

Testosterone should always be part of the conversation: women produce testosterone, and levels tend to decline with age. Testosterone is not a weight-loss drug, and it should not be prescribed casually. But in properly selected women, it may be relevant to low sexual desire, reduced arousal, fatigue, motivation, wellbeing and quality of life. This matters because a woman may present with “low energy”, “brain fog”, “loss of drive” or “not feeling like herself” and be offered only weight-loss treatment or indeed HRT but without considering testosterone. The problem may be partly  hormonal and partly lifestlye so its critical to consider all relevant factors.

At ProLongevity, our view is simple: GLP-1s can be a valuable metabolic tool, but they should sit within a broader menopause-aware plan. That means reviewing HRT, considering testosterone where appropriate, prioritising protein and resistance training, and measuring health improvements beyond the number on the scales.

The biggest mistake: losing muscle while losing weight

For menopausal women, weight loss alone is not the goal. The real goal is to lose visceral fat while preserving  (or ideally building)  lean muscle.  This is crucial because muscle is not just “tone”. It is a metabolic organ. It helps regulate glucose disposal, insulin sensitivity, strength, balance, independence and healthy ageing.

During and after menopause, women are already at greater risk of: